Sativex Receives Qualifying Notice for Approval From Health Canada

GW Pharmaceuticals and Bayer HealthCare Pharmaceuticals announced that Health Canada issued a qualifying notice for the approval of Sativex for the relief of cancer pain.

GW filed the application in October 2006 with the agency. The approved indication will be “adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain,” GW said.

Sativex has been developed by UK-based GW Pharmaceuticals and is exclusively marketed in Canada by Bayer.